Vertex Pharmaceuticals (WBO:VRTX) Other Operating Expense : €0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Other Operating Expense?

Vertex Pharmaceuticals's Other Operating Expense for the three months ended in Dec. 2023 was €0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0 Mil.

Vertex Pharmaceuticals's quarterly Other Operating Expense declined from Jun. 2023 (€-0 Mil) to Sep. 2023 (€-0 Mil) but then increased from Sep. 2023 (€-0 Mil) to Dec. 2023 (€0 Mil).

Vertex Pharmaceuticals's annual Other Operating Expense increased from Dec. 2021 (€-0 Mil) to Dec. 2022 (€0 Mil) and increased from Dec. 2022 (€0 Mil) to Dec. 2023 (€0 Mil).

Vertex Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Vertex Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Other Operating Expense Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

Vertex Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Vertex Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Vertex Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (WBO:VRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX34:Brazil

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.